«上一篇/Previous Article|本期目录/Table of Contents|下一篇/Next Article»

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:

27卷

期数:

2021年01期

页码:

43-46

栏目:

临床医学

出版日期:

2021-01-20

文章信息/Info

Title:

Single center retrospective analysis of sorafenib in the treatment of hepatocellular carcinoma recurrence after liver transplantation

文章编号:

1006-8147（2021）01-0043-04

作者:

罗宇涵¹; 蒋文涛²; 李俊杰²

1.天津医科大学研究生院，天津 300070；2.天津市第一中心医院肝移植科，天津 300192

Author(s):

LUO Yu-han¹; JIANG Wen-tao²; LI Jun-jie²

1.Graduate School，Tianjin Medical University，Tianjin 300070，China； 2.Department of Liver Transplantation，Tianjin First Central Hospital， Tianjin 300192，China

关键词:

索拉非尼; 最佳支持治疗; 肝细胞癌复发; 肝移植

Keywords:

sorafenib; best supportive treatment; hepatocellular carcinoma recurrence; liver transplantation

分类号:

R735.7

DOI:

-

文献标志码:

A

摘要:

目的：通过收集分析单中心索拉非尼治疗肝移植后肝细胞癌复发人群数据，探讨索拉非尼在肝细胞癌肝移植患者中的应用。方法：收集2011—2016年在天津市第一中心医院肝移植术后肝细胞癌复发使用索拉非尼和最佳支持治疗（BSC）的患者资料41例。索拉非尼组27例，BSC组14例。比较两组的生存时间差异，并探讨索拉非尼的安全性。结果：索拉非尼组复发后生存时间为4～48个月，中位生存时间11个月；BSC组生存时间1～24个月，中位生存时间4个月，两组中位生存时间差异具有统计学意义（P＜0.01）。27例服药患者资料中，不良事件发生率不高，3级以上1例，该患者严重腹泻，予停药。结论：服用索拉非尼整体生存率较BSC高，部分患者用药后可出现轻微不良事件。索拉非尼可以较好改善肝移植后肝细胞癌复发患者预后。

Abstract:

Objective: To investigate the application of sorafenib in patients with hepatocellular carcinoma liver transplantation by collecting and analyzing the single-center data of sorafenib in the treatment of hepatocellular carcinoma recurrence after liver transplantation. Methods: The data of 41 patients who used sorafenib and best supportive care（BSC）for hepatocellular carcinoma recurrence after liver transplantation in Tianjin First Central Hospital from 2011 to 2016 were collected. The patients were divided into sorafenib group（27 cases） and BSC group（14 cases）. The difference in survival time was compared and the safety of sorafenib was discussed. Results: The survival time was 4-48 months and the median survival time after recurrence was 11 months in the sorafenib group；the survival time was 1-24 months and the median survival time after recurrence was 4 months in the BSC group. There was a statistically significant difference in median survival time between the two groups（P<0.01）. In the data of 27 patients taking medication, the incidence of adverse events（AEs） was not high. One patient with grade 3 or above had severe diarrhea and was stopped medication. Conclusion: The overall survival rate of patients taking sorafenib is higher than that of the BSC group, and some patients may have mild adverse events after taking the drug. Sorafenib can better improve the prognosis of patients with hepatocellular carcinoma recurrence after liver transplantation.

参考文献/References:

[1] Mazzaferro V，Regalia E，Doci R，et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med，1996，334（11）:693
[2] Clavien P A，Lesurtel M，Bossuyt P M，et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report[J]. Lancet Oncol，2012， 13（1）:e11
[3] European Association for the Study of the Liver Electronic Address: Easloffice@Easloffice eu. EASL clinical practice guidelines: liver transplantation[J]. J Hepatol，2016，64（2）:433
[4] Wang P，Li H，Shi B J，et al. Prognostic factors in patients with recurrent hepatocellular carcinoma treated with salvage liver transplantation: a single-center study[J]. Oncotarget，2016 ，7（23）:35071
[5] Roayaie S，Schwartz J D，Sung M W，et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis[J]. Liver Transpl，2004，10（4）:534
[6] Davis E，Wiesner R，Valdecasas J，et al. Treatment of recurrent hepatocellular carcinoma after liver transplantation[J]. Liver Transplantation，2011，17（S2）:S162
[7] Llovet J M，Ricci S，Mazzaferro V，et al. Sorafenib in advanced hepatocellular carcinoma [J]. N Engl J Med，2008，359（4）:378
[8] 陈婧. 索拉非尼治疗肝癌肝移植术后复发的疗效[J]. 中国实用医药，2017，12（8）:121
[9] 陈建斌，陈国勇，孙建军，等. 索拉非尼治疗肝癌肝移植术后肿瘤复发的临床疗效观察[J]. 器官移植 ，2013，4（2）:98
[10] Kang S H，Cho H，Cho E J，et al. Efficacy of sorafenib for the treatment of post-transplant hepatocellular carcinoma recurrence[J]. J Korean Med Sci，2018，33（45）:e283
[11] Weinmann A，Niederle I M，Koch S，et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation[J]. Dig Liver Dis，2012，44（5）:432
[12] 陈冰锋，潘楚芝，陈署贤，等. 索拉非尼预防原发性肝癌根治性治疗术后复发的临床效果[J]. 中华肝脏 外科手术学电子杂志，2016， 5（1）:38
[13] 郑树森，程启阳，耿磊，等. 肝癌肝移植术后肝癌复发研究新进展[J]. 中国普通外科杂志，2019，28（ 7）:773
[14] 王征，周俭. 肝癌肝移植术后的综合治疗[J].中华肝脏病杂志，2013，21（5）:324
[15] Berumen J，Hemming A. Liver transplantation for hepatocellular carcinoma[J].Abdominal radiology （New York），2018，43（1）:185
[16] 陆雷，王轩，张斌，等. 索拉非尼治疗肝细胞性肝癌肝移植后的复发[J]. 中国组织工程研究，2012，16 （31）:5706
[17] 成建斌，江雪梅，刘鹏，等. 肝癌肝移植术后复发的干预措施疗效评价：网状荟萃分析[J]. 中华移植杂 志:电子版，2018，12（4）:183
[18] 王梓轩. 索拉非尼治疗转移性肾癌的临床效果[J].河南医学研究，2019，28（15）:2760
[19] Sposito C，Mariani L，Germini A，et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case- control study[J]. J Hepatol，2013，59（1）:59
[20] De′angelis N，Landi F，Nencioni M，et al. Role of sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation[J]. Prog Transplant，2016，26（4）:348
[21] Piguet A C，Saar B，Hlushchuk R，et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma[Z]. 2011
[22] 袁冰，李晓蔻，谭煌英. mTOR抑制剂依维莫司在肿瘤临床中的应用进展[J]. 中日友好医院学报，2020， 34（2）:101
[23] Bhoori S，Toffanin S，Sposito C，et al. Personalized molecular targeted therapy in advanced ，recurrent hepatocellular carcinoma after liver transplantation: a proof of principle[J]. J Hepatol，2010，52（5）:771
[24] Koeberle D，Dufour J F，Demeter G，et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma （HCC）: a randomized multicenter，multinational phase Ⅱ trial （SAKK 77/08 and SASL 29）[J]. Ann Oncol，2016，27（5）:856
[25] 牟迪. 仑伐替尼治疗恶性实体瘤的研究进展[J]. 中国肿瘤生物治疗杂志，2020，27（4）:445
[26] 杨文君，文元元，燕丹. 临床药师参与一例肝细胞癌患者瑞格非尼治疗的药学实践[J]. 东南大学学报： 医学版，2020，39（1）:62
[27] 吕晓雯，王甦. 瑞戈非尼治疗肝细胞癌的机制及临床效果[J]. 临床肝胆病杂志，2020，36（5）:1175

相似文献/References:

备注/Memo

备注/Memo:

基金项目 国家自然科学基金（81870444）；天津市自然科学基金（19JCQNJC10300）
作者简介 罗宇涵（1995-），男，硕士在读，研究方向：外科学，器官移植；通信作者：蒋文涛，E-mail： jiangwentao@nankai.edu.cn。

常用功能

更新日期/Last Update: 2021-01-10